Manufacturer of Controlled Substances; Notice of Application, 65404 [E8-26145]
Download as PDF
<![CDATA[
sroberts on PROD1PC70 with NOTICES
65404
Federal Register / Vol. 73, No. 213 / Monday, November 3, 2008 / Notices
Act (‘‘CERCLA’’), 42 U.S.C. 9607(a), and
Section 311 of the Clean Water Act
(‘‘CWA’’), 33 U.S.C. 1321, for damages
for injury to, destruction of, or loss of
natural resources in or near Kingman,
Kansas, resulting from the release of
anhydrous ammonia from a pipeline
owned and operated by Defendants on
or about October 27, 2004.
In the Consent Decree, the Defendants
have agreed to pay a total of $452,535
to the Trustees as Natural Resource
Damages including past Natural
Resource Damage Assessment costs. The
Consent Decree also requires the
Defendants to purchase a specified 160
acre parcel of property with natural
resources equivalent to those injured,
lost and destroyed by the ammonia
release and transfer it to the Wichita
State University Foundation, a non
profit that will use the property for
biological research and preserve it in
perpetuity.
For thirty (30) days after the date of
this publication, the Department of
Justice will receive comments relating to
the Consent Decree. Comments should
be addressed to the Assistant Attorney
General, Environment and Natural
Resources Division, and either e-mailed
to pubcomment-ees.enrd@usdoj.gov or
mailed to P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611. In either case, the
comments should refer to United States
of America, The State of Kansas v.
Magellan Ammonia Pipeline, et al.,
Civil Action No. 08–cv–2532 Ref. No.
90–5–1–1–06074/3.
During the comment period, the
Consent Decree may be examined on the
following Department of Justice Web
site: https://www.usdoj.gov/enrd/
Consent_Decrees.html. A copy of the
Consent Decree may also be examined at
the Office of the United States Attorney,
Western District of Washington, 700
Stewart Street Suite 5220, Seattle, WA
98101–1271 (206) 553–7970. A copy of
the Consent Decree may also be
obtained by mail from the Consent
Decree Library, P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611, or by faxing or e-mailing a
request to Tonia Fleetwood
(tonia.fleetwood@usdoj.gov), fax no.
(202) 514–0097, phone confirmation
number (202) 514–1547. In requesting a
copy from the Consent Decree Library,
please enclose a check in the amount of
$13 (25 cents per page reproduction
cost) payable to the United States
Treasury or, if by e-mail or fax, forward
VerDate Aug<31>2005
16:58 Oct 31, 2008
Jkt 217001
a check in that amount to the Consent
Decree Library at the stated address.
Maureen Katz,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources.
[FR Doc. E8–26077 Filed 10–31–08; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 15, 2008,
Cedarburg Pharmaceuticals, Inc., 870
Badger Circle, Grafton, Wisconsin
53024, made application by renewal to
the Drug Enforcement Administration
(DEA) as a bulk manufacturer of the
basic classes of controlled substances
listed in schedules I and II:
Drug
Schedule
Tetrahydrocannabinols (7370) .....
Dihydromorphine (9145) ...............
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
I
I
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 2, 2009.
Dated: October 28, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–26145 Filed 10–31–08; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00121
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Office of Justice Programs
[OJP (OJP) Docket No. 1491]
Hearing of the Review Panel on Prison
Rape
Office of Justice Programs,
Justice.
ACTION: Notice of hearing.
AGENCY:
SUMMARY: The Office of Justice Programs
(OJP) announces that the Review Panel
on Prison Rape (Panel) will hold a
hearing in Culpeper, Virginia on
November 14, 2008. The hearing time
and location are noted below.The
purpose of the hearing is to assist the
Bureau of Justice Statistics (BJS) in
identifying common characteristics of
victims and perpetrators of rape in
county jails, and the characteristics of
U.S. jails with the highest and lowest
incidence of rape, based on an
anonymous survey by BJS of inmates in
a representative sample of jails. On June
25, 2008, BJS issued the report Sexual
Victimization in Local Jails Reported by
Inmates, 2007. The report provides a
listing of local jails grouped according
to the prevalence of reported sexual
victimization, and it formed the basis of
the Panel’s decision about which
facilities would be the subject of
testimony.
DATES: Friday, November 14, 2008, 11
a.m. to 5:30 p.m. (Culpeper County,
Virginia Jail—facility with a low
prevalence of reported sexual
victimization).
ADDRESSES: The hearing will take place
at the County Administration Building,
302 North Main Street, Culpeper,
Virginia 22701.
FOR FURTHER INFORMATION CONTACT:
Christopher Zubowicz, Designated
Federal Official, OJP,
christopher.zubowicz@usdoj.gov, (202)
307–0690. (Note: This is not a toll-free
number.)
SUPPLEMENTARY INFORMATION: The Panel,
which was established pursuant to the
Prison Rape Elimination Act of 2003,
Public Law 108–79, 117 Stat. 972
(codified as amended at 42 U.S.C.
15601–15609 (2006)), will hold its next
hearing to carry out the review
functions specified at 42 U.S.C.
15603(b)(3)(A). Testimony from the
hearing will assist the Panel in carrying
out its statutory obligations and in
identifying best practices for deterring
rape in county jails. Space is limited at
the hearing location. Special needs
requests should be made to Christopher
Zubowicz, Designated Federal Official,
OJP, christopher.zubowicz@usdoj.gov or
E:\FR\FM\03NON1.SGM
03NON1
]]>Agencies
[Federal Register Volume 73, Number 213 (Monday, November 3, 2008)]
[Notices]
[Page 65404]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-26145]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on July 15, 2008, Cedarburg
Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024,
made application by renewal to the Drug Enforcement Administration
(DEA) as a bulk manufacturer of the basic classes of controlled
substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)............... I
Dihydromorphine (9145)..................... I
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Hydrocodone (9193)......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than January 2, 2009.
Dated: October 28, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-26145 Filed 10-31-08; 8:45 am]
BILLING CODE 4410-09-P
